EFFECTS OF EMPAGLIFLOZIN IN FEMALE AND MALE PATIENTS WITH HEART FAILURE AND PRESERVED EJECTION FRACTION: RESULTS FROM THE EMPEROR-PRESERVED TRIAL

被引：0
|
作者：
Butler, Javed [1 ]
机构：
[1] Univ Mississippi, Sch Med, Jackson, MS USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2022年 / 79卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：311 / 311
页数：1
相关论文
共 50 条
  • [1] EMPAGLIFLOZIN IN HEART FAILURE WITH A PRESERVED EJECTION FRACTION ≥50%: RESULTS FROM THE EMPEROR-PRESERVED CLINICAL TRIAL
    Yousef, Zaheer
    [J]. HEART, 2022, 108 : A79 - A80
  • [2] Empagliflozin in Heart Failure With a Preserved Ejection Fraction ≥50% - Results From the EMPEROR-Preserved Clinical Trial
    Anker, Stefan D.
    [J]. CIRCULATION, 2021, 144 (25) : E571 - E572
  • [3] Effects of empagliflozin in patients with heart failure and preserved ejection fraction according to baseline diuretic use: results from the EMPEROR-Preserved trial
    Butler, J.
    [J]. EUROPEAN HEART JOURNAL, 2022, 43 : 982 - 982
  • [4] Association of heart rate with heart failure outcomes and the effects of empagliflozin in patients with preserved ejection fraction - EMPEROR-Preserved trial
    Boehm, M.
    Anker, S. D.
    Mahfoud, F.
    Filippatos, G.
    Ferreira, J. P.
    Pocock, S. J.
    Brueckmann, M.
    Linetzky, B.
    Schueler, E.
    Wanner, C.
    Zannad, F.
    Packer, M.
    Butler, J.
    [J]. EUROPEAN HEART JOURNAL, 2022, 43 : 983 - 983
  • [5] Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction EMPEROR-Preserved Trial
    Packer, Milton
    Butler, Javed
    Zannad, Faiez
    Filippatos, Gerasimos
    Ferreira, Joao Pedro
    Pocock, Stuart J.
    Carson, Peter
    Anand, Inder
    Doehner, Wolfram
    Haass, Markus
    Komajda, Michel
    Miller, Alan
    Pehrson, Steen
    Teerlink, John R.
    Schnaidt, Sven
    Zeller, Cordula
    Schnee, Janet M.
    Anker, Stefan D.
    [J]. CIRCULATION, 2021, 144 (16) : 1284 - 1294
  • [6] Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR-Preserved trial
    Butler, Javed
    Siddiqi, Tariq Jamal
    Filippatos, Gerasimos
    Ferreira, Joao Pedro
    Pocock, Stuart J.
    Zannad, Faiez
    Anker, Stefan D.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 (02) : 245 - 248
  • [7] Uric Acid and Treatment With Empagliflozin in Heart Failure With Preserved Ejection Fraction: The EMPEROR-Preserved Trial
    Doehner, Wolfram
    [J]. CIRCULATION, 2022, 146
  • [8] EMPEROR-Preserved: Empagliflozin and Outcomes in Heart Failure with a Preserved Ejection Fraction and CKD
    Zannad, Faiez
    Kraus, Bettina J.
    Zeller, Cordula
    Pocock, Stuart
    Packer, Milton
    Filippatos, Gerasimos
    Ferreira, Joao Pedro
    Anker, Stefan D.
    Butler, Javed
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : B3 - B3
  • [9] Liver tests, cardiovascular outcomes and effects of empagliflozin in patients with heart failure and preserved ejection fraction: The EMPEROR-Preserved trial
    Boehm, Michael
    Butler, Javed
    Krawczyk, Marcin
    Mahfoud, Felix
    Haring, Bernhard
    Filippatos, Gerasimos
    Ferreira, Joao Pedro J.
    Pocock, Stuart
    Brueckmann, Martina
    Ofstad, Anne Pernille
    Schueler, Elke
    Wanner, Christoph
    Verma, Subodh
    Packer, Milton D.
    Anker, Stefan
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 (08) : 1375 - 1383
  • [10] Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial
    Butler, Javed
    Filippatos, Gerasimos
    Siddiqi, Tariq Jamal
    Brueckmann, Martina
    Bohm, Michael
    Chopra, Vijay K.
    Ferreira, Joao Pedro
    Januzzi, James L.
    Kaul, Sanjay
    Pina, Ileana L.
    Ponikowski, Piotr
    Shah, Sanjiv J.
    Senni, Michele
    Vedin, Ola
    Verma, Subodh
    Peil, Barbara
    Pocock, Stuart J.
    Zannad, Faiez
    Packer, Milton
    Anker, Stefan D.
    [J]. CIRCULATION, 2022, 145 (03) : 184 - 193
12345